Overview

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This is a phase II, one-arm study, which is aiming to evaluate the feasibility of combination of Disitamab Vedotin, Sintilimab and S-1 as conversion therapy in patients with HER2 overexpression unresectable gastric cancer .

Phase:

Phase 2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel
Tegafur